product

Justin Neill discusses new approaches to reaction monitoring for small molecule structure analysis

Posted: 27 November 2018 | | No comments yet

BrightSpec is first to commercialise molecular rotational resonance (MRR) spectroscopy for drug discovery and process R&D applications.

Justin Neill, CTO of BrightSpec, describes using a cross-technique lab services approach to enantiomer, diastereomer and regioisomer characterisation using BrightSpec MRR and BioTools VCD instruments at SCIX in Atlanta, October 2018.

Click here to learn more about BrightSpec, and click here to learn about BioTools.

Video taken at SCIX, October 2018. 

If you would like to be contacted by BrightSpec, please complete the form below:






 

Send this to a friend